BioCryst Pharmaceuticals BCRX Right of use assets, net
Right of use assets, net at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:RightOfUseAssetsNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's right of use assets, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's right of use assets, net?
- BioCryst Pharmaceuticals (BCRX) reported right of use assets, net of $13.62M in Q1 2026.
- How has BioCryst Pharmaceuticals's right of use assets, net changed year-over-year?
- BioCryst Pharmaceuticals's right of use assets, net increased by 13.6% year-over-year, from $11.98M to $13.62M.
- What is the long-term trend for BioCryst Pharmaceuticals's right of use assets, net?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's right of use assets, net has grown at a -11.4% compound annual growth rate (CAGR), from $13M to $10.2M.
- What does right of use assets, net mean?
- This represents the capitalized value of the right to use leased assets, such as office space or laboratory facilities, over the remaining lease term. It reflects the company's long-term commitment to leased infrastructure necessary for research and development operations. Monitoring this balance helps investors understand the scale of the company's physical footprint and its long-term lease obligations.